世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

トランスレーショナル再生医療市場レポート：2024-2034


Translational Regenerative Medicine Market Report 2024-2034

レポート詳細 トランスレーショナル再生医療市場レポート 2024-2034 ：本レポートは、業界とその根底にあるダイナミクスをより良く理解することを望むなら、新たな収益ポケットを目指す大手企業にと... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
Visiongain
ヴィジョンゲイン社 		2024年2月9日 GBP5,150
部署ライセンス
ライセンス・価格情報
注文方法はこちら 		270 248 英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

レポート詳細

トランスレーショナル再生医療市場レポート 2024-2034：本レポートは、業界とその根底にあるダイナミクスをより良く理解することを望むなら、新たな収益ポケットを目指す大手企業にとって貴重なものとなるでしょう。異業種への進出や新たな地域での既存事業の拡大を目指す企業にも有用です。

慢性疾患の増加が業界の成長を牽引

世界のヘルスケアは、慢性疾患の蔓延によってパラダイムシフトが起きている。心血管疾患、糖尿病、神経変性疾患、自己免疫疾患などの疾患は、世界中の医療システムに大きな負担を強いている。このような健康危機の高まりを受けて、トランスレーショナル再生医療（TRM）という分野が、これらの慢性疾患の根本原因に対処する革新的な解決策を提供する希望の光として浮上してきた。トランスレーショナル再生医療は、損傷した組織や臓器を修復、置換、再生するために、身体が本来持っている再生能力を活用することに焦点を当てている。幹細胞治療、組織工学、その他の再生アプローチは、単に症状を管理するのではなく、根本的な原因に対処することで、慢性疾患の治療状況を一変させる可能性を秘めている。トランスレーショナル再生医療は、個々の患者のニーズに合わせた個別化治療の開発を可能にする。このアプローチは、患者の反応の不均一性が一般的である慢性疾患において特に適切である。人工多能性幹細胞（iPSC）や成体幹細胞の使用を含む幹細胞研究の進歩は、多様な再生の可能性を提供している。幹細胞を用いた治療法は、損傷した膵臓細胞を置換することで正常なインスリン産生を回復させることができる糖尿病などの疾患に対して有望である。

トランスレーショナル再生医療に伴う高額な開発費

トランスレーショナルな再生医療治療法を開発する初期段階には、基礎となる生物学とメカニズムを理解するための広範な研究が必要である。この初期段階の研究には、研究所の設備、人員、消耗品などの資金が必要である。臨床試験は開発費用の大部分を占める。これらの臨床試験は、ヒトを対象とした再生療法の安全性と有効性を評価するために不可欠である。費用には、患者の募集、モニタリング、規制遵守、データ解析などが含まれ、これらすべてに多額の財源が必要となる。実験室規模の製造から大規模製造への移行には、特有の課題がある。より大規模な再生療法の再現性、品質、安全性を確保するためには、製造インフラとプロセスの最適化への投資が必要である。再生医療製品の上市に成功しても、それは始まりに過ぎない。企業は、マーケティング、流通、市販後調査など、市場参入に関連する追加コストに直面する。これらの活動は、普及と継続的な成功を確実にするために極めて重要である。

市場調査レポートを購入する前にすべき質問とは？

  • トランスレーショナル再生医療市場はどのように進化しているのか？
  • トランスレーショナル再生医療市場の推進要因と阻害要因は何か？
  • トランスレーショナル再生医療の各サブマーケットは予測期間中にどのように成長し、2034年にはどれくらいの収益を占めるようになるのか？
  • 2024年から2034年にかけて、トランスレーショナル再生医療の各サブマーケットの市場シェアはどのように推移するのか？
  • 2024年から2034年にかけて、市場全体を牽引する主な要因は何か？
  • 主要なトランスレーショナル再生医療市場はマクロ経済のダイナミクスに広く追随するのか、それとも個々の国の市場が他を凌駕するのか？
  • 2034年までに各国市場のシェアはどのように変化し、どの地域が2034年の市場をリードするのか。
  • 主要プレーヤーと予測期間中の見通しは？
  • これらの大手企業のトランスレーショナル再生医療プロジェクトとは？
  • 2024年から2034年の間に、業界はどのように進化するのか？トランスレーショナル
  • 現在、そして今後10年間に行われる再生医療プロジェクトは？
  • トランスレーショナル再生医療市場をさらに拡大するために、製品の商業化の必要性は高まっているか？
  • トランスレーショナル再生医療市場はどこに向かっているのか、そしてどのようにすれば市場の最前線に立てるのか？
  • 新商品や新サービスに最適な投資方法とは？
  • 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

このことがトランスレーショナル再生医療市場に現在、そして今後10年間でどのような影響を与えるかを知る必要がある：

  • 270ページに及ぶレポートには、104の表と144の図表が掲載されている。
  • について本レポートでは、業界の主要な有利分野を取り上げている。今すぐ
  • 世界、地域、国の売上高と成長に関する詳細な分析が含まれている。
  • 競合他社が成功した主なトレンド、変化、収益予測をハイライトします。

本レポートは、トランスレーショナル再生医療市場が今後10年間にどのように発展していくのか、またCOVID-19の景気後退と好転の変動に合わせてどのように発展していくのかをお伝えします。この市場は、過去10年間のどの時点よりも今が重要である。

2034年までの予測やその他の分析から、商業的な展望が明らかになる

  • 2034年までの収益予測に加え、最近の実績、成長率、市場シェアも提供している。
  • ビジネスの展望や展開など、独自の分析が掲載されている。
  • 定性的分析（市場ダイナミクス、促進要因、機会、阻害要因、課題を含む）、および最近の動向をご覧いただけます。

本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。

レポート対象セグメント

製品別

  • 幹細胞治療自己幹細胞、同種幹細胞
  • 組織工学足場、ハイドロゲル
  • 遺伝子治療
  • その他

用途別

  • 腫瘍学
  • 皮膚科学
  • 筋骨格系
  • 神経学
  • 心臓血管
  • 創傷治癒
  • 眼科
  • その他

世界市場全体と各分野の売上予測に加え、5つの地域と17の主要国市場の売上予測も掲載しています：

北米

  • 米国
  • カナダ

欧州

  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他の欧州

アジア太平洋

  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • その他のアジア太平洋

ラテンアメリカ

  • ブラジル
  • メキシコ
  • その他のラテンアメリカ

MEA

  • GCC
  • 南アフリカ
  • その他のMEA

本レポートには、トランスレーショナル再生医療市場2024-2034における主要企業のプロファイルも含まれており、これらの企業の事業のこのセグメントに焦点を当てている。

報告書に掲載されている主要企業

  • Amgen Inc.
  • Anterogen Co., Ltd.
  • AVITA Medical, Inc.
  • Biosolutions Ltd.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Integra LifeSciences
  • Mesoblast Ltd.
  • Novartis AG
  • Organogenesis Inc.
  • Sarepta Therapeutics, Inc.
  • Smith+Nephew
  • TERUMO BCT, INC.

 

トランスレーショナル再生医療市場の2024年から2034年までの世界全体の売上高は、金額ベースでは2024年に770億米ドルを突破する。2034年まで力強い収益成長を予測。当社の調査では、最も大きな可能性を秘めた組織を特定しています。彼らの能力、進歩、商業的展望を発見し、一歩先を行くお手伝いをします。

トランスレーショナル再生医療市場 2024-2034」レポートはどのようにお役に立ちますか？

要約すると、270ページに及ぶ本レポートは、以下のような知識を提供する：

  • トランスレーショナル再生医療市場の2024年から2034年までの収益予測、製品別・用途別に世界・地域レベルで予測 - 業界の将来性を発見し、投資と収益に最も有利な場所を見つけることができます。
  • 5つの地域と20の主要国市場の2034年までの収益予測 - 北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEAのトランスレーショナル再生医療市場の2024年から2034年までの予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要経済圏の市場も予測しています。
  • 2024年から2034年までのトランスレーショナル再生医療市場に関わる主要企業14社の企業プロファイルを含む。

独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。

他にはない情報

私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。弊社の調査レポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、トランスレーショナル再生医療市場2024年から2034年、市場をリードする企業の商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。



ページTOPに戻る


目次

目次

1 レポート概要
1.1 研究の目的
1.2 トランスレーショナル再生医療市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて

2 エグゼクティブ・サマリー

3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場促進要因
3.2.1.1 戦略的活動とコラボレーションの増加
3.2.1.2 研究開発プロジェクトの増加
3.2.1.3 政府支援の急増
3.2.1.4 個別化医療への注目の高まり
3.2.1.5 新たな治療領域での応用の出現
3.2.1.6 主要市場プレイヤーによる共同研究やパートナーシップの増加
3.2.1.7 再生医療における規制承認の増加
3.2.2 市場抑制要因
3.2.2.1 膨大な数の製品回収
3.2.2.2 市場における未承認製品
3.2.2.3 保険償還政策
3.2.2.4 治療費の高騰
3.2.3 市場機会
3.2.3.1 世界の先進国および発展途上国における研究パートナーシップの拡大
3.2.3.2 医学研究の進歩に対する意識の高まり
3.2.3.3 投資と資金調達の拡大
3.2.3.4 3Dプリンティングの可能性の活用
3.2.3.5 人工知能やビッグデータとの統合
3.2.3.6 臓器移植件数の増加
3.3 COVID-19インパクト分析
3.4 ポーターのファイブフォース分析
3.4.1 サプライヤーの交渉力
3.4.2 買い手の交渉力
3.4.3 競争相手のライバル関係
3.4.4 代替品による脅威
3.4.5 新規参入企業の脅威
3.5 PEST分析

4 トランスレーショナル再生医療市場分析：製品別
4.1 主要な調査結果
4.2 用途別セグメント 市場魅力度指数
4.3 製品別トランスレーショナル再生医療市場規模推定と予測
4.4 幹細胞治療
4.4.1 幹細胞治療によるトランスレーショナル再生医療市場規模の推定と予測
4.4.2 2024-2034年地域別市場規模（US$ Billion）
4.4.3 地域別市場シェア、2024年・2034年(%)
4.4.4 自己幹細胞療法
4.4.4.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.4.2 地域別市場シェア、2024年・2034年(%)
4.4.5 アロジェニック
4.4.5.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.5.2 地域別市場シェア、2024年・2034年(%)
4.5 組織工学
4.5.1 組織工学によるトランスレーショナル再生医療市場規模の推定と予測
4.5.2 2024〜2034年の地域別市場規模（US$ Billion）
4.5.3 地域別市場シェア、2024年・2034年(%)
4.5.4 足場
4.5.4.1 2024〜2034年の地域別市場規模（US$ Billion）
4.5.4.2 地域別市場シェア、2024年・2034年(%)
4.5.5 ハイドロゲル
4.5.5.1 2024〜2034年の地域別市場規模（US$ Billion）
4.5.5.2 地域別市場シェア、2024年・2034年(%)
4.6 遺伝子治療
4.6.1 2024〜2034年の地域別市場規模（US$ Billion）
4.6.2 地域別市場シェア、2024年・2034年(%)
4.7 その他
4.7.1 2024〜2034年の地域別市場規模（US$ Billion）
4.7.2 地域別市場シェア、2024年・2034年(%)

5 トランスレーショナル再生医療市場分析：用途別
5.1 主要な調査結果
5.2 用途別セグメント 市場魅力度指数
5.3 用途別トランスレーショナル再生医療市場規模の推定と予測
5.4 がん領域
5.4.1 2024〜2034年の地域別市場規模（US$ Billion）
5.4.2 地域別市場シェア、2024年・2034年(%)
5.5 皮膚科領域
5.5.1 2024〜2034年の地域別市場規模（US$ Billion）
5.5.2 地域別市場シェア、2024年・2034年(%)
5.6 筋骨格系
5.6.1 2024〜2034年の地域別市場規模（US$ Billion）
5.6.2 地域別市場シェア、2024年・2034年(%)
5.7 神経
5.7.1 2024〜2034年の地域別市場規模（US$ Billion）
5.7.2 地域別市場シェア、2024年・2034年(%)
5.8 循環器
5.8.1 2024〜2034年の地域別市場規模（US$ Billion）
5.8.2 地域別市場シェア、2024年・2034年(%)
5.9 創傷治癒
5.9.1 2024〜2034年の地域別市場規模（US$ Billion）
5.9.2 地域別市場シェア、2024年・2034年(%)
5.10 眼科領域
5.10.1 2024〜2034年の地域別市場規模（US$ Billion）
5.10.2 地域別市場シェア、2024年・2034年(%)
5.11 その他
5.11.1 2024〜2034年の地域別市場規模（US$ Billion）
5.11.2 地域別市場シェア、2024年・2034年(%)

6 トランスレーショナル再生医療市場分析：地域別
6.1 主要な調査結果
6.2 地域別市場規模の推定と予測

7 北米のトランスレーショナル再生医療市場分析
7.1 主要な調査結果
7.2 北米のトランスレーショナル再生医療市場魅力度指数
7.3 北米のトランスレーショナル再生医療市場の国別推移、2024年、2029年、2034年（US$ Billion）
7.4 北米のトランスレーショナル再生医療市場規模推定と予測：国別
7.5 北米のトランスレーショナル再生医療市場規模推定と予測：製品別
7.6 北米のトランスレーショナル再生医療市場規模推定と予測：用途別
7.7 米国のトランスレーショナル再生医療市場分析
7.8 カナダのトランスレーショナル再生医療市場分析

8 欧州のトランスレーショナル再生医療市場分析
8.1 主要な調査結果
8.2 欧州のトランスレーショナル再生医療市場魅力度指数
8.3 欧州のトランスレーショナル再生医療市場の国別市場規模、2024年、2029年、2034年（US$ Billion）
8.4 欧州のトランスレーショナル再生医療市場規模推定と予測：国別
8.5 欧州のトランスレーショナル再生医療市場規模推定と予測：製品別
8.6 欧州のトランスレーショナル再生医療市場規模推定と予測：用途別
8.7 ドイツのトランスレーショナル再生医療市場分析
8.8 フランスのトランスレーショナル再生医療市場分析
8.9 イギリスのトランスレーショナル再生医療市場分析
8.10 イタリアのトランスレーショナル再生医療市場分析
8.11 スペインのトランスレーショナル再生医療市場分析
8.12 ロシアのトランスレーショナル再生医療市場分析
8.13 その他の欧州のトランスレーショナル再生医療市場分析

9 アジア太平洋地域のトランスレーショナル再生医療市場分析
9.1 主要な調査結果
9.2 アジア太平洋地域のトランスレーショナル再生医療市場魅力度指数
9.3 アジア太平洋地域のトランスレーショナル再生医療市場の国別市場規模、2024年、2029年、2034年（US$ Billion）
9.4 アジア太平洋地域のトランスレーショナル再生医療市場規模推定と予測：国別
9.5 アジア太平洋地域のトランスレーショナル再生医療市場規模推定と予測：製品別
9.6 アジア太平洋地域のトランスレーショナル再生医療市場規模推定と予測：用途別
9.7 日本のトランスレーショナル再生医療市場分析
9.8 中国のトランスレーショナル再生医療市場分析
9.9 インドのトランスレーショナル再生医療市場分析
9.10 オーストラリアのトランスレーショナル再生医療市場分析
9.11 韓国のトランスレーショナル再生医療市場分析
9.12 その他のアジア太平洋地域のトランスレーショナル再生医療市場分析

10 ラテンアメリカのトランスレーショナル再生医療市場分析
10.1 主要な調査結果
10.2 ラテンアメリカのトランスレーショナル再生医療市場魅力度指数
10.3 ラテンアメリカのトランスレーショナル再生医療市場の国別市場規模、2024年、2029年、2034年（US$ Billion）
10.4 ラテンアメリカのトランスレーショナル再生医療市場規模推定と予測：国別
10.5 ラテンアメリカのトランスレーショナル再生医療市場規模推定と予測：製品別
10.6 ラテンアメリカのトランスレーショナル再生医療市場規模推定と予測：用途別
10.7 ブラジルのトランスレーショナル再生医療市場分析
10.8 メキシコのトランスレーショナル再生医療市場分析
10.9 その他のラテンアメリカのトランスレーショナル再生医療市場分析

11 MEAのトランスレーショナル再生医療市場分析
11.1 主要な調査結果
11.2 MEAのトランスレーショナル再生医療市場魅力度指数
11.3 MEAのトランスレーショナル再生医療国別市場、2024年、2029年、2034年（US$ Billion）
11.4 MEAのトランスレーショナル再生医療市場規模推定と予測：国別
11.5 MEAのトランスレーショナル再生医療市場規模推定と予測：製品別
11.6 MEAのトランスレーショナル再生医療市場規模推定と予測：用途別
11.7 GCCのトランスレーショナル再生医療市場分析
11.8 南アフリカのトランスレーショナル再生医療市場分析
11.9 その他のMEAトランスレーショナル再生医療市場分析

12 主要企業のプロフィール
12.1 競争環境、2022年
12.2 戦略的展望
12.3  Amgen Inc.
12.3.1 会社概要
12.3.2 会社概要
12.3.3 財務分析
12.3.3.1 純収入、2017-2022年
12.3.3.2 R＆D、2017-2022年
12.3.3.3 地域市場シェア、2022年
12.3.4 製品ベンチマーク
12.3.5 戦略的展望
12.4 Anterogen Co., Ltd.
12.4.1 会社概要
12.4.2 会社概要
12.4.3 製品ベンチマーク
12.5 AVITA Medical, Inc.
12.5.1 会社概要
12.5.2 会社概要
12.5.3 財務分析
12.5.3.1 純収入、2017-2022年
12.5.3.2 売上高、2017-2022年
12.5.4 製品ベンチマーク
12.5.5 戦略的展望
12.6 Biosolutions Ltd.
12.6.1 会社概要
12.6.2 会社概要
12.6.3 製品ベンチマーク
12.6.4 戦略的展望
12.7 bluebird bio, Inc.
12.7.1 会社概要
12.7.2 会社概要
12.7.3 財務分析
12.7.3.1 純収入、2017-2022年
12.7.3.2 売上高、2017-2022年
12.7.4 製品ベンチマーク
12.7.5 戦略的展望
12.8  Bristol-Myers Squibb Company
12.8.1 会社概要
12.8.2 会社概要
12.8.3 財務分析
12.8.3.1 純収入、2017-2022年
12.8.3.2 R＆D、2017年〜2022年
12.8.3.3 地域市場シェア、2022年
12.8.4 製品ベンチマーク
12.8.5 戦略的展望
12.9 Gilead Sciences, Inc.
12.9.1 会社概要
12.9.2 会社概要
12.9.3 財務分析
12.9.3.1 純収入、2017-2022年
12.9.3.2 R＆D、2017年〜2022年
12.9.3.3 地域市場シェア、2022年
12.9.4 製品ベンチマーク
12.9.5 戦略的展望
12.10 Integra LifeSciences
12.10.1 会社概要
12.10.2 会社概要
12.10.3 財務分析
12.10.3.1 純収入、2017-2022年
12.10.3.2 R＆D、2017-2022年
12.10.3.3 地域市場シェア、2022年
12.10.4 製品ベンチマーク
12.10.5 戦略的展望
12.11 Mesoblast Ltd.
12.11.1 会社概要
12.11.2 会社概要
12.11.3 財務分析
12.11.3.1 純収入、2017-2022年
12.11.3.2 R＆D、2017-2022年
12.11.4 製品のベンチマーキング
12.11.5 戦略的展望
12.12 Novartis AG
12.12.1 会社概要
12.12.2 会社概要
12.12.3 財務分析
12.12.3.1 純収入、2017-2022年
12.12.3.2 R＆D、2017-2022年
12.12.3.3 地域市場シェア、2022年
12.12.4 製品ベンチマーク
12.12.5 戦略的展望
12.13 Organogenesis Inc.
12.13.1 会社概要
12.13.2 会社概要
12.13.3 財務分析
12.13.3.1 純収入、2017-2022年
12.13.3.2 R＆D、2017-2022年
12.13.4 製品ベンチマーク
12.13.5 戦略的展望
12.14 Sarepta Therapeutics, Inc.
12.14.1 会社概要
12.14.2 会社概要
12.14.3 財務分析
12.14.3.1 純収入、2017-2022年
12.14.3.2 R＆D、2017-2022年
12.14.4 製品ベンチマーク
12.14.5 戦略的展望
12.15 Smith+Nephew
12.15.1 会社概要
12.15.2 会社概要
12.15.3 財務分析
12.15.3.1 純収入、2017-2022年
12.15.3.2 R＆D、2017年〜2022年
12.15.3.3 地域市場シェア、2022年
12.15.4 製品ベンチマーク
12.15.5 戦略的展望
12.16 TERUMO BCT, INC.
12.16.1 会社概要
12.16.2 会社概要
12.16.3 財務分析
12.16.3.1 純収入、2017-2022年
12.16.3.2 地域市場シェア（2021年
12.16.4 製品ベンチマーク
12.16.5 戦略的展望

13 結論と提言
13.1 Visiongainからの結びの言葉
13.2 市場プレイヤーへの提言

 

ページTOPに戻る



図表リスト

表の一覧
Table 1 Translational Regenerative Medicine Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 7 Translational Regenerative Medicine Market Forecast by Stem Cell Therapy, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 8 Stem Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 9 Autologous Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 10 Allogenic Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 11 Tissue Engineering Market Forecast by Stem Cell Therapy, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Scaffold Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Hydrogels Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Gene Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Dermatology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Musculoskeletal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Neurology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 22 Cardiovascular Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Wound Healing Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Ophthalmology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 26 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 North America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 28 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 29 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 U.S. Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Canada Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 32 Europe Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 34 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Germany Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 36 France Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 37 UK Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Italy Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 39 Spain Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 Russia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 Rest of Europe Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Asia Pacific Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 44 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 Japan Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 China Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 India Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 48 Australia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 49 South Korea Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Rest of Asia Pacific Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 51 Latin America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 53 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Brazil Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 55 Mexico Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Rest of Latin America Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 MEA Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 59 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 GCC Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 South Africa Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Rest of MEA Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 63 Strategic Outlook
Table 64 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 65 Amgen Inc.: Product Benchmarking
Table 66 Amgen Inc. : Strategic Outlook
Table 67 Anterogen Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 68 Anterogen Co., Ltd.: Product Benchmarking
Table 69 AVITA Medical, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 AVITA Medical, Inc.: Product Benchmarking
Table 71 AVITA Medical, Inc.: Strategic Outlook
Table 72 Biosolutions Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Biosolutions Ltd.: Product Benchmarking
Table 74 Biosolutions Ltd.: Strategic Outlook
Table 75 bluebird bio, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 bluebird bio, Inc.: Product Benchmarking
Table 77 bluebird bio, Inc.: Strategic Outlook
Table 78 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Bristol-Myers Squibb Company: Product Benchmarking
Table 80 Bristol-Myers Squibb Company: Strategic Outlook
Table 81 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Gilead Sciences, Inc.: Product Benchmarking
Table 83 Gilead Sciences, Inc.: Strategic Outlook
Table 84 Integra LifeSciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Integra LifeSciences: Product Benchmarking
Table 86 Integra LifeSciences: Strategic Outlook
Table 87 Mesoblast Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Mesoblast Ltd.: Product Benchmarking
Table 89 Mesoblast Ltd.: Strategic Outlook
Table 90 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Novartis AG: Product Benchmarking
Table 92 Novartis AG: Strategic Outlook
Table 93 Organogenesis Inc.:(CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Organogenesis Inc.: Product Benchmarking
Table 95 Organogenesis Inc.: Strategic Outlook
Table 96 Sarepta Therapeutics, Inc. :(CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Sarepta Therapeutics, Inc.: Product Benchmarking
Table 98 Sarepta Therapeutics, Inc..: Strategic Outlook
Table 99 Smith+Nephew: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Smith+Nephew: Product Benchmarking
Table 101 Smith+Nephew: Strategic Outlook
Table 102 TERUMO BCT, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 TERUMO BCT, INC.: Product Benchmarking
Table 104 TERUMO BCT, INC.: Strategic Outlook
 
図の一覧
Figure 1 Translational Regenerative Medicine Market Segmentation
Figure 2 Translational Regenerative Medicine Market by Product: Market Attractiveness Index
Figure 3 Translational Regenerative Medicine Market by Application: Market Attractiveness Index
Figure 4 Translational Regenerative Medicine Market Attractiveness Index by Region
Figure 5 Translational Regenerative Medicine Market: Market Dynamics
Figure 6 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 7 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 8 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 9 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 10 Translational Regenerative Medicine Market: Porter’s Five Forces Analysis
Figure 11 Translational Regenerative Medicine Market: PEST Analysis
Figure 12 Translational Regenerative Medicine Market by Product: Market Attractiveness Index
Figure 13 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 14 Translational Regenerative Medicine Market Share Forecast by Product, 2024 2029, 2034 (%)
Figure 15 Stem Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 16 Stem Cell Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 17 Autologous Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 18 Autologous Stem Cell Therapy Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 Allogenic Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 Allogenic Stem Cell Therapy Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 22 Tissue Engineering Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Scaffold Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 24 Scaffold Tissue Engineering Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Hydrogels Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 26 Hydrogels Tissue Engineering Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Gene Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 28 Gene Therapy Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 30 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Translational Regenerative Medicine Market by Application: Market Attractiveness Index
Figure 32 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 33 Translational Regenerative Medicine Market Share Forecast by Application, 2024 2029, 2034 (%)
Figure 34 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 35 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 36 Dermatology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 37 Dermatology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 38 Musculoskeletal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 39 Musculoskeletal Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 40 Neurology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 41 Neurology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 42 Cardiovascular Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 43 Cardiovascular Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 44 Wound Healing Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 45 Wound Healing Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Ophthalmology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 47 Ophthalmology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 49 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Translational Regenerative Medicine Market Forecast by Region 2023 and 2033 (Revenue, CAGR %)
Figure 51 Translational Regenerative Medicine Market Share Forecast by Region 2024 2029, 2034 (%)
Figure 52 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 North America Translational Regenerative Medicine Market Attractiveness Index
Figure 54 North America Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 55 North America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 56 North America Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 57 North America Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 58 North America Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 59 North America Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 60 North America Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 61 U.S. Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 62 Canada Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 63 Europe Translational Regenerative Medicine Market Attractiveness Index
Figure 64 Europe Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 65 Europe Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 66 Europe Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 67 Europe Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 68 Europe Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 69 Europe Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 70 Europe Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 71 Germany Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 72 France Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 73 UK Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 74 Italy Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 75 Spain Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 76 Russia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 77 Rest of Europe Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 78 Asia Pacific Translational Regenerative Medicine Market Attractiveness Index
Figure 79 Asia Pacific Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 80 Asia Pacific Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 81 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 82 Asia Pacific Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 83 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 84 Asia Pacific Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 85 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 86 Japan Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 87 China Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 88 India Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 89 Australia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 90 South Korea Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 91 Rest of Asia Pacific Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 92 Latin America Translational Regenerative Medicine Market Attractiveness Index
Figure 93 Latin America Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 94 Latin America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 95 Latin America Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 96 Latin America Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 97 Latin America Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 98 Latin America Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 99 Latin America Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 100 Brazil Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 101 Mexico Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 102 Rest of Latin America Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 103 MEA Translational Regenerative Medicine Market Attractiveness Index
Figure 104 MEA Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 105 MEA Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 106 MEA Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 107 MEA Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 108 MEA Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 109 MEA Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 110 MEA Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 111 GCC Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 112 South Africa Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 113 Rest of MEA Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 114 Translational Regenerative Medicine Market: Company Share, 2022
Figure 115 Amgen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 116 Amgen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 117 Amgen Inc.: Regional Market Shares, 2022
Figure 118 AVITA Medical, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 119 AVITA Medical, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 120 bluebird bio, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 121 bluebird bio, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 122 Bristol-Myers Squibb Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 123 Bristol-Myers Squibb Company: R&D, 2017-2022 (US$ Million, AGR%)
Figure 124 Bristol-Myers Squibb Company: Regional Market Shares, 2022
Figure 125 Gilead Sciences, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 126 Gilead Sciences, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 127 Gilead Sciences, Inc.: Regional Market Shares, 2022
Figure 128 Integra LifeSciences: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 129 Integra LifeSciences: R&D, 2017-2022 (US$ Million, AGR%)
Figure 130 Integra LifeSciences: Regional Market Shares, 2022
Figure 131 Mesoblast Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 132 Mesoblast Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 133 Novartis AG: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 134 Novartis AG: R&D, 2017-2022 (US$ Million, AGR%)
Figure 135 Novartis AG: Regional Market Shares, 2022
Figure 136 Organogenesis Inc.: Net Revenue, 2017-2022 (US$ million, AGR%)
Figure 137 Organogenesis Inc.: R&D, 2017-2022 (US$ million, AGR%)
Figure 138 Sarepta Therapeutics, Inc..: Net Revenue, 2017-2022 (US$ million, AGR%)
Figure 139 Sarepta Therapeutics, Inc.: R&D, 2017-2022 (US$ million, AGR%)
Figure 140 Smith+Nephew: Net Revenue, 2017-2022 (US$ million, AGR%)
Figure 141 Smith+Nephew: R&D, 2017-2022 (US$ million, AGR%)
Figure 142 Smith+Nephew: Regional Market Shares, 2022
Figure 143 TERUMO BCT, INC.: Net Revenue, 2017-2022 (US$ million, AGR%)
Figure 144 TERUMO BCT, INC.: Regional Market Shares, 2022

　

ページTOPに戻る


　

Summary

Report Details

The Translational Regenerative Medicine Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Chronic Diseases Driving Industry Growth

The global landscape of healthcare is witnessing a paradigm shift driven by the escalating prevalence of chronic diseases. Conditions such as cardiovascular diseases, diabetes, neurodegenerative disorders, and autoimmune diseases pose a significant burden on healthcare systems worldwide. In response to this growing health crisis, the field of Translational regenerative medicine (TRM) has emerged as a beacon of hope, offering innovative solutions to address the root causes of these chronic ailments. Translational regenerative medicine focuses on harnessing the body’s innate regenerative capabilities to repair, replace, or regenerate damaged tissues and organs. Stem cell therapies, tissue engineering, and other regenerative approaches hold the potential to revolutionize the treatment landscape for chronic diseases by addressing the underlying causes rather than merely managing symptoms. Translational regenerative medicine allows for the development of personalized therapies tailored to individual patient needs. This approach is particularly relevant in the context of chronic diseases where heterogeneity in patient responses is common. Advances in stem cell research, including the use of induced pluripotent stem cells (iPSCs) and adult stem cells, offer a diverse range of regenerative possibilities. Stem cell-based therapies hold promise for conditions such as diabetes, where the replacement of damaged pancreatic cells could restore normal insulin production.

High Development Costs Associated with Translational Regenerative Medicine

The initial phases of developing translational regenerative medicine therapies involve extensive research to understand the underlying biology and mechanisms. This early-stage research requires funding for laboratory equipment, personnel, and consumables. Clinical trials represent a major portion of the development costs. These trials are essential for evaluating the safety and efficacy of regenerative therapies in human subjects. Costs include patient recruitment, monitoring, regulatory compliance, and data analysis, all of which demand substantial financial resources. Transitioning from laboratory-scale production to large-scale manufacturing presents unique challenges. Ensuring the reproducibility, quality, and safety of regenerative therapies on a larger scale requires investment in manufacturing infrastructure and process optimization. Successfully bringing a regenerative medicine product to market is just the beginning. Companies face additional costs related to market access, including marketing, distribution, and post-marketing surveillance. These activities are crucial for ensuring widespread adoption and continued success.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the Translational Regenerative Medicine Market evolving?
  • What is driving and restraining the Translational Regenerative Medicine Market?
  • How will each Translational Regenerative Medicine submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each Translational Regenerative Medicine submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading Translational Regenerative Medicine Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Translational Regenerative Medicine projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of Translational
  • Regenerative Medicine projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Translational Regenerative Medicine Market?
  • Where is the Translational Regenerative Medicine Market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Translational Regenerative Medicine Market today, and over the next 10 years:

  • Our 270-page report provides 104 tables and 144 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Translational Regenerative Medicine Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

By Product

  • Stem Cell Therapy: Autologous, Allogenic
  • Tissue Engineering: Scaffold, Hydrogels
  • Gene Therapy
  • Others

By Application

  • Oncology
  • Dermatology
  • Musculoskeletal
  • Neurology
  • Cardiovascular
  • Wound Healing
  • Ophthalmology
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 17 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Translational Regenerative Medicine Market 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

  • Amgen Inc.
  • Anterogen Co., Ltd.
  • AVITA Medical, Inc.
  • Biosolutions Ltd.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Integra LifeSciences
  • Mesoblast Ltd.
  • Novartis AG
  • Organogenesis Inc.
  • Sarepta Therapeutics, Inc.
  • Smith+Nephew
  • TERUMO BCT, INC.

Overall world revenue for Translational Regenerative Medicine Market, 2024 to 2034 in terms of value the market will surpass US$77.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Translational Regenerative Medicine Market 2024 to 2034 report help you?

In summary, our 270-page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for Translational Regenerative Medicine Market 2024 to 2034, with forecasts for product and application each forecasted at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the Translational Regenerative Medicine Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 14 of the major companies involved in the Translational Regenerative Medicine Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Translational Regenerative Medicine Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.



ページTOPに戻る


Table of Contents

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Translational Regenerative Medicine Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Strategic Activities and Collaborations
3.2.1.2 Rise in Research and Development Projects
3.2.1.3 Surging Government Support
3.2.1.4 Growing Focus on Personalized Medicine
3.2.1.5 Emerging Applications in New Therapeutic Areas
3.2.1.6 Increasing Collaborations and Partnerships by Major Market Players
3.2.1.7 Increasing Regulatory Approvals in Regenerative Medicine
3.2.2 Market Restraining Factors
3.2.2.1 Substantial Number of Product Recalls
3.2.2.2 Unapproved Products in the Market
3.2.2.3 Reimbursement Policies
3.2.2.4 High Cost of Treatments
3.2.3 Market Opportunities
3.2.3.1 Growing Research Partnership in Developed and Developing Countries Across the Globe
3.2.3.2 Growing Awareness About the Advances in Medical Research
3.2.3.3 Growing Investment and Funding
3.2.3.4 Harnessing the Potential of 3D Printing
3.2.3.5 Integration with Artificial Intelligence and Big Data
3.2.3.6 Growing Number of Organ Transplants
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis

4 Translational Regenerative Medicine Market Analysis by Product
4.1 Key Findings
4.2 Application Segment: Market Attractiveness Index
4.3 Translational Regenerative Medicine Market Size Estimation and Forecast by Product
4.4 Stem Cell Therapy
4.4.1 Translational Regenerative Medicine Market Size Estimation and Forecast by Stem Cell Therapy
4.4.2 Market Size by Region, 2024-2034 (US$ Billion)
4.4.3 Market Share by Region, 2024 & 2034 (%)
4.4.4 Autologous Stem Cell Therapy
4.4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.4.2 Market Share by Region, 2024 & 2034 (%)
4.4.5 Allogenic
4.4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.5.2 Market Share by Region, 2024 & 2034 (%)
4.5 Tissue Engineering
4.5.1 Translational Regenerative Medicine Market Size Estimation and Forecast by Tissue Engineering
4.5.2 Market Size by Region, 2024-2034 (US$ Billion)
4.5.3 Market Share by Region, 2024 & 2034 (%)
4.5.4 Scaffold
4.5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.4.2 Market Share by Region, 2024 & 2034 (%)
4.5.5 Hydrogels
4.5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Gene Therapy
4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.6.2 Market Share by Region, 2024 & 2034 (%)
4.7 Others
4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
4.7.2 Market Share by Region, 2024 & 2034 (%)

5 Translational Regenerative Medicine Market Analysis by Application
5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 Translational Regenerative Medicine Market Size Estimation and Forecast by Application
5.4 Oncology
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Dermatology
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Musculoskeletal
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Neurology
5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Cardiovascular
5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
5.8.2 Market Share by Region, 2024 & 2034 (%)
5.9 Wound Healing
5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
5.9.2 Market Share by Region, 2024 & 2034 (%)
5.10 Ophthalmology
5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
5.10.2 Market Share by Region, 2024 & 2034 (%)
5.11 Others
5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
5.11.2 Market Share by Region, 2024 & 2034 (%)

6 Translational Regenerative Medicine Market Analysis by Region
6.1 Key Findings
6.2 Regional Market Size Estimation and Forecast

7 North America Translational Regenerative Medicine Market Analysis
7.1 Key Findings
7.2 North America Translational Regenerative Medicine Market Attractiveness Index
7.3 North America Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
7.4 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Country
7.5 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Product
7.6 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Application
7.7 U.S. Translational Regenerative Medicine Market Analysis
7.8 Canada Translational Regenerative Medicine Market Analysis

8 Europe Translational Regenerative Medicine Market Analysis
8.1 Key Findings
8.2 Europe Translational Regenerative Medicine Market Attractiveness Index
8.3 Europe Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
8.4 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Country
8.5 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Product
8.6 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Application
8.7 Germany Translational Regenerative Medicine Market Analysis
8.8 France Translational Regenerative Medicine Market Analysis
8.9 UK Translational Regenerative Medicine Market Analysis
8.10 Italy Translational Regenerative Medicine Market Analysis
8.11 Spain Translational Regenerative Medicine Market Analysis
8.12 Russia Translational Regenerative Medicine Market Analysis
8.13 Rest of Europe Translational Regenerative Medicine Market Analysis

9 Asia Pacific Translational Regenerative Medicine Market Analysis
9.1 Key Findings
9.2 Asia Pacific Translational Regenerative Medicine Market Attractiveness Index
9.3 Asia Pacific Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
9.4 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Country
9.5 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Product
9.6 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Application
9.7 Japan Translational Regenerative Medicine Market Analysis
9.8 China Translational Regenerative Medicine Market Analysis
9.9 India Translational Regenerative Medicine Market Analysis
9.10 Australia Translational Regenerative Medicine Market Analysis
9.11 South Korea Translational Regenerative Medicine Market Analysis
9.12 Rest of Asia Pacific Translational Regenerative Medicine Market Analysis

10 Latin America Translational Regenerative Medicine Market Analysis
10.1 Key Findings
10.2 Latin America Translational Regenerative Medicine Market Attractiveness Index
10.3 Latin America Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
10.4 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Country
10.5 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Product
10.6 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Application
10.7 Brazil Translational Regenerative Medicine Market Analysis
10.8 Mexico Translational Regenerative Medicine Market Analysis
10.9 Rest of Latin America Translational Regenerative Medicine Market Analysis

11 MEA Translational Regenerative Medicine Market Analysis
11.1 Key Findings
11.2 MEA Translational Regenerative Medicine Market Attractiveness Index
11.3 MEA Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Country
11.5 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Product
11.6 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Application
11.7 GCC Translational Regenerative Medicine Market Analysis
11.8 South Africa Translational Regenerative Medicine Market Analysis
11.9 Rest of MEA Translational Regenerative Medicine Market Analysis

12 Company Profiles
12.1 Competitive Landscape, 2022
12.2 Strategic Outlook
12.3 Amgen Inc.
12.3.1 Company Snapshot
12.3.2 Company Overview
12.3.3 Financial Analysis
12.3.3.1 Net Revenue, 2017-2022
12.3.3.2 R&D, 2017-2022
12.3.3.3 Regional Market Shares, 2022
12.3.4 Product Benchmarking
12.3.5 Strategic Outlook
12.4 Anterogen Co., Ltd.
12.4.1 Company Snapshot
12.4.2 Company Overview
12.4.3 Product Benchmarking
12.5 AVITA Medical, Inc.
12.5.1 Company Snapshot
12.5.2 Company Overview
12.5.3 Financial Analysis
12.5.3.1 Net Revenue, 2017-2022
12.5.3.2 R&D, 2017-2022
12.5.4 Product Benchmarking
12.5.5 Strategic Outlook
12.6 Biosolutions Ltd.
12.6.1 Company Snapshot
12.6.2 Company Overview
12.6.3 Product Benchmarking
12.6.4 Strategic Outlook
12.7 bluebird bio, Inc.
12.7.1 Company Snapshot
12.7.2 Company Overview
12.7.3 Financial Analysis
12.7.3.1 Net Revenue, 2017-2022
12.7.3.2 R&D, 2017-2022
12.7.4 Product Benchmarking
12.7.5 Strategic Outlook
12.8 Bristol-Myers Squibb Company
12.8.1 Company Snapshot
12.8.2 Company Overviews
12.8.3 Financial Analysis
12.8.3.1 Net Revenue, 2017-2022
12.8.3.2 R&D, 2017-2022
12.8.3.3 Regional Market Shares, 2022
12.8.4 Product Benchmarking
12.8.5 Strategic Outlook
12.9 Gilead Sciences, Inc.
12.9.1 Company Snapshot
12.9.2 Company Overview
12.9.3 Financial Analysis
12.9.3.1 Net Revenue, 2017-2022
12.9.3.2 R&D, 2017-2022
12.9.3.3 Regional Market Shares, 2022
12.9.4 Product Benchmarking
12.9.5 Strategic Outlook
12.10 Integra LifeSciences
12.10.1 Company Snapshot
12.10.2 Company Overview
12.10.3 Financial Analysis
12.10.3.1 Net Revenue, 2017-2022
12.10.3.2 R&D, 2017-2022
12.10.3.3 Regional Market Shares, 2022
12.10.4 Product Benchmarking
12.10.5 Strategic Outlook
12.11 Mesoblast Ltd.
12.11.1 Company Snapshot
12.11.2 Company Overview
12.11.3 Financial Analysis
12.11.3.1 Net Revenue, 2017-2022
12.11.3.2 R&D, 2017-2022
12.11.4 Product Benchmarking
12.11.5 Strategic Outlook
12.12 Novartis AG
12.12.1 Company Snapshot
12.12.2 Company Overview
12.12.3 Financial Analysis
12.12.3.1 Net Revenue, 2017-2022
12.12.3.2 R&D, 2017-2022
12.12.3.3 Regional Market Shares, 2022
12.12.4 Product Benchmarking
12.12.5 Strategic Outlook
12.13 Organogenesis Inc.
12.13.1 Company Snapshot
12.13.2 Company Overview
12.13.3 Financial Analysis
12.13.3.1 Net Revenue, 2017-2022
12.13.3.2 R&D, 2017-2022
12.13.4 Product Benchmarking
12.13.5 Strategic Outlook
12.14 Sarepta Therapeutics, Inc.
12.14.1 Company Snapshot
12.14.2 Company Overview
12.14.3 Financial Analysis
12.14.3.1 Net Revenue, 2017-2022
12.14.3.2 R&D, 2017-2022
12.14.4 Product Benchmarking
12.14.5 Strategic Outlook
12.15 Smith+Nephew
12.15.1 Company Snapshot
12.15.2 Company Overview
12.15.3 Financial Analysis
12.15.3.1 Net Revenue, 2017-2022
12.15.3.2 R&D, 2017-2022
12.15.3.3 Regional Market Shares, 2022
12.15.4 Product Benchmarking
12.15.5 Strategic Outlook
12.16 TERUMO BCT, INC.
12.16.1 Company Snapshot
12.16.2 Company Overview
12.16.3 Financial Analysis
12.16.3.1 Net Revenue, 2017-2022
12.16.3.2 Regional Market Shares, 2021
12.16.4 Product Benchmarking
12.16.5 Strategic Outlook

13 Conclusion and Recommendations
13.1 Concluding Remarks from Visiongain
13.2 Recommendations for Market Players

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1 Translational Regenerative Medicine Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 7 Translational Regenerative Medicine Market Forecast by Stem Cell Therapy, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 8 Stem Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 9 Autologous Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 10 Allogenic Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 11 Tissue Engineering Market Forecast by Stem Cell Therapy, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Scaffold Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Hydrogels Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Gene Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Dermatology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Musculoskeletal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Neurology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 22 Cardiovascular Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Wound Healing Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Ophthalmology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 26 Translational Regenerative Medicine Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 North America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 28 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 29 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 U.S. Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Canada Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 32 Europe Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 34 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Germany Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 36 France Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 37 UK Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Italy Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 39 Spain Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 Russia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 Rest of Europe Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Asia Pacific Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 44 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 Japan Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 China Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 India Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 48 Australia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 49 South Korea Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Rest of Asia Pacific Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 51 Latin America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 53 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Brazil Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 55 Mexico Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Rest of Latin America Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 MEA Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 59 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 GCC Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 South Africa Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Rest of MEA Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 63 Strategic Outlook
Table 64 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 65 Amgen Inc.: Product Benchmarking
Table 66 Amgen Inc. : Strategic Outlook
Table 67 Anterogen Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 68 Anterogen Co., Ltd.: Product Benchmarking
Table 69 AVITA Medical, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 AVITA Medical, Inc.: Product Benchmarking
Table 71 AVITA Medical, Inc.: Strategic Outlook
Table 72 Biosolutions Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Biosolutions Ltd.: Product Benchmarking
Table 74 Biosolutions Ltd.: Strategic Outlook
Table 75 bluebird bio, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 bluebird bio, Inc.: Product Benchmarking
Table 77 bluebird bio, Inc.: Strategic Outlook
Table 78 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Bristol-Myers Squibb Company: Product Benchmarking
Table 80 Bristol-Myers Squibb Company: Strategic Outlook
Table 81 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Gilead Sciences, Inc.: Product Benchmarking
Table 83 Gilead Sciences, Inc.: Strategic Outlook
Table 84 Integra LifeSciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Integra LifeSciences: Product Benchmarking
Table 86 Integra LifeSciences: Strategic Outlook
Table 87 Mesoblast Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Mesoblast Ltd.: Product Benchmarking
Table 89 Mesoblast Ltd.: Strategic Outlook
Table 90 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Novartis AG: Product Benchmarking
Table 92 Novartis AG: Strategic Outlook
Table 93 Organogenesis Inc.:(CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Organogenesis Inc.: Product Benchmarking
Table 95 Organogenesis Inc.: Strategic Outlook
Table 96 Sarepta Therapeutics, Inc. :(CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Sarepta Therapeutics, Inc.: Product Benchmarking
Table 98 Sarepta Therapeutics, Inc..: Strategic Outlook
Table 99 Smith+Nephew: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Smith+Nephew: Product Benchmarking
Table 101 Smith+Nephew: Strategic Outlook
Table 102 TERUMO BCT, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 TERUMO BCT, INC.: Product Benchmarking
Table 104 TERUMO BCT, INC.: Strategic Outlook
 
List of Figures
Figure 1 Translational Regenerative Medicine Market Segmentation
Figure 2 Translational Regenerative Medicine Market by Product: Market Attractiveness Index
Figure 3 Translational Regenerative Medicine Market by Application: Market Attractiveness Index
Figure 4 Translational Regenerative Medicine Market Attractiveness Index by Region
Figure 5 Translational Regenerative Medicine Market: Market Dynamics
Figure 6 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 7 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 8 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 9 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 10 Translational Regenerative Medicine Market: Porter’s Five Forces Analysis
Figure 11 Translational Regenerative Medicine Market: PEST Analysis
Figure 12 Translational Regenerative Medicine Market by Product: Market Attractiveness Index
Figure 13 Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 14 Translational Regenerative Medicine Market Share Forecast by Product, 2024 2029, 2034 (%)
Figure 15 Stem Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 16 Stem Cell Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 17 Autologous Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 18 Autologous Stem Cell Therapy Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 Allogenic Stem Cell Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 Allogenic Stem Cell Therapy Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 22 Tissue Engineering Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Scaffold Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 24 Scaffold Tissue Engineering Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Hydrogels Tissue Engineering Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 26 Hydrogels Tissue Engineering Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Gene Therapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 28 Gene Therapy Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 30 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Translational Regenerative Medicine Market by Application: Market Attractiveness Index
Figure 32 Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 33 Translational Regenerative Medicine Market Share Forecast by Application, 2024 2029, 2034 (%)
Figure 34 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 35 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 36 Dermatology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 37 Dermatology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 38 Musculoskeletal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 39 Musculoskeletal Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 40 Neurology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 41 Neurology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 42 Cardiovascular Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 43 Cardiovascular Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 44 Wound Healing Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 45 Wound Healing Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Ophthalmology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 47 Ophthalmology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 49 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Translational Regenerative Medicine Market Forecast by Region 2023 and 2033 (Revenue, CAGR %)
Figure 51 Translational Regenerative Medicine Market Share Forecast by Region 2024 2029, 2034 (%)
Figure 52 Translational Regenerative Medicine Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 North America Translational Regenerative Medicine Market Attractiveness Index
Figure 54 North America Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 55 North America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 56 North America Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 57 North America Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 58 North America Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 59 North America Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 60 North America Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 61 U.S. Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 62 Canada Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 63 Europe Translational Regenerative Medicine Market Attractiveness Index
Figure 64 Europe Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 65 Europe Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 66 Europe Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 67 Europe Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 68 Europe Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 69 Europe Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 70 Europe Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 71 Germany Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 72 France Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 73 UK Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 74 Italy Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 75 Spain Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 76 Russia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 77 Rest of Europe Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 78 Asia Pacific Translational Regenerative Medicine Market Attractiveness Index
Figure 79 Asia Pacific Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 80 Asia Pacific Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 81 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 82 Asia Pacific Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 83 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 84 Asia Pacific Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 85 Asia Pacific Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 86 Japan Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 87 China Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 88 India Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 89 Australia Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 90 South Korea Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 91 Rest of Asia Pacific Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 92 Latin America Translational Regenerative Medicine Market Attractiveness Index
Figure 93 Latin America Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 94 Latin America Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 95 Latin America Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 96 Latin America Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 97 Latin America Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 98 Latin America Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 99 Latin America Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 100 Brazil Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 101 Mexico Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 102 Rest of Latin America Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 103 MEA Translational Regenerative Medicine Market Attractiveness Index
Figure 104 MEA Translational Regenerative Medicine Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 105 MEA Translational Regenerative Medicine Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 106 MEA Translational Regenerative Medicine Market Share Forecast by Country, 2024 & 2034 (%)
Figure 107 MEA Translational Regenerative Medicine Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 108 MEA Translational Regenerative Medicine Market Share Forecast by Product, 2024 & 2034 (%)
Figure 109 MEA Translational Regenerative Medicine Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 110 MEA Translational Regenerative Medicine Market Share Forecast by Application, 2024 & 2034 (%)
Figure 111 GCC Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 112 South Africa Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 113 Rest of MEA Translational Regenerative Medicine Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 114 Translational Regenerative Medicine Market: Company Share, 2022
Figure 115 Amgen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
Figure 116 Amgen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 117 Amgen Inc.: Regional Market Shares, 2022
Figure 118 AVITA Medical, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 119 AVITA Medical, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 120 bluebird bio, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 121 bluebird bio, Inc.: R&D, 2017-2022 (US$ Million, AGR %)
Figure 122 Bristol-Myers Squibb Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 123 Bristol-Myers Squibb Company: R&D, 2017-2022 (US$ Million, AGR%)
Figure 124 Bristol-Myers Squibb Company: Regional Market Shares, 2022
Figure 125 Gilead Sciences, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 126 Gilead Sciences, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 127 Gilead Sciences, Inc.: Regional Market Shares, 2022
Figure 128 Integra LifeSciences: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 129 Integra LifeSciences: R&D, 2017-2022 (US$ Million, AGR%)
Figure 130 Integra LifeSciences: Regional Market Shares, 2022
Figure 131 Mesoblast Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 132 Mesoblast Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 133 Novartis AG: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 134 Novartis AG: R&D, 2017-2022 (US$ Million, AGR%)
Figure 135 Novartis AG: Regional Market Shares, 2022
Figure 136 Organogenesis Inc.: Net Revenue, 2017-2022 (US$ million, AGR%)
Figure 137 Organogenesis Inc.: R&D, 2017-2022 (US$ million, AGR%)
Figure 138 Sarepta Therapeutics, Inc..: Net Revenue, 2017-2022 (US$ million, AGR%)
Figure 139 Sarepta Therapeutics, Inc.: R&D, 2017-2022 (US$ million, AGR%)
Figure 140 Smith+Nephew: Net Revenue, 2017-2022 (US$ million, AGR%)
Figure 141 Smith+Nephew: R&D, 2017-2022 (US$ million, AGR%)
Figure 142 Smith+Nephew: Regional Market Shares, 2022
Figure 143 TERUMO BCT, INC.: Net Revenue, 2017-2022 (US$ million, AGR%)
Figure 144 TERUMO BCT, INC.: Regional Market Shares, 2022

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（ medicine）の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Visiongain社はどのような調査会社ですか?


英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15　10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.